Bahrain authorises Covid-19 drug Sotrovimab for emergency use

TDT | Manama

The Daily Tribune – www.newsofbahrain.com

The National Health Regulatory Authority (NHRA) has approved Sotrovimab for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19.

The decision to add Sotrovimab to COVID-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well as a comprehensive review of GSK’s clinical trials.

Sotrovimab-VIR-7831 develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation.

Safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalisation for more than 24 hours and a reduction in the number of fatalities by 85% when administered at an early stage of treatment.

Bahrain has authorised the emergency use of six vaccines, namely Sinopharm, Pfizer/BioNTech, AstraZeneca’s Covishield, Johnson & Johnson, Sputnik V and Sputnik Light.